
|Articles|February 24, 2014
- Gastrointestinal Cancers (Issue 1)
- Volume 1
- Issue 1
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Author(s)Robert L. Fine, MD
Robert L. Fine, MD, from Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Advertisement
Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Read more abouta hedgehog pathway inhibitor for the treatment of advanced pancreatic cancer > >
Articles in this issue
almost 12 years ago
The Identification of Molecular Subtypes of Gastric Canceralmost 12 years ago
Ramucirumab Combo Increases Survival in Gastric Canceralmost 12 years ago
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Dataalmost 12 years ago
New Standard of Neoadjuvant Care for Rectal Cancer Establishedalmost 12 years ago
Vismodegib Demonstrates Activity in Advanced Pancreatic Canceralmost 12 years ago
The Treatment of Advanced Colorectal Canceralmost 12 years ago
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















